Nasdaq · CIK 0001501989
CTMX CytomX Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Mar 19, 2026. Close $2.57 on Oct 9, 2026, +4% from the 52-week low and -62% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
CTMXOct 9, 2026 · close 2.57
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CytomX Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Marcia Belvin SVP, Chief Scientific Officer sell | $202k 31,492 shares | -9% | +1162% from low-19% from high | |
| 22Weak | Sean A. McCarthy CEO sell | $462k 101,793 shares | -9% | +870% from low-0% from high | |
| 21Weak | Marcia Belvin SVP, Chief Scientific Officer sell | $37k 13,884 shares | -5% | +469% from low-18% from high | |
| 36Weak | Sean A. McCarthy CEO sell | $149k 55,511 shares | -5% | +469% from low-18% from high | |
| 28Weak | Christopher Ogden Chief Financial Officer sell | $33k 12,255 shares | -6% | +537% from low-8% from high | |
| 30Weak | Marcia Belvin SVP, Chief Scientific Officer sell | $12k 19,512 shares | -7% | - | |
| 30Weak | Yu-Waye Chu Chief Medical Officer sell | $2,411 4,025 shares | -3% | - | |
| 30Weak | Lloyd A Rowland General Counsel sell | $6,112 10,203 shares | -8% | - | |
| 37Weak | Christopher Ogden Chief Financial Officer sell | $5,122 8,551 shares | -4% | - | |
| 40Moderate | Sean A. McCarthy CEO sell | $23k 37,656 shares | -4% | - |
Transactions
The last 51 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Marcia Belvin SVP, Chief Scientific Officer | SOpen-market sale Common Stock | -31,492 | $6.42 | $202k | 300,760 | Mar 19, 2026 |
| Feb 2, 2026 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 332,252 | Feb 4, 2026 |
| Feb 2, 2026 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Feb 4, 2026 |
| Nov 6, 2025 | Sean A. McCarthy CEO | SOpen-market sale Class A Common Stock10b5-1 | -101,793 | $4.54 | $462k | 987,891 | Nov 10, 2025 |
| Oct 20, 2025 | Rachael Lester Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Oct 29, 2025 |
| Sep 26, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +78,250 | $0.00 | $0 | 78,250 | Sep 30, 2025 |
| Sep 26, 2025 | Sean A. McCarthy CEO | AGrant or award Stock Option (Right to Buy)derivative | +570,000 | $0.00 | $0 | 570,000 | Sep 30, 2025 |
| Sep 26, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +87,500 | $0.00 | $0 | 87,500 | Sep 30, 2025 |
| Sep 26, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,300 | $0.00 | $0 | 36,300 | Sep 30, 2025 |
| Sep 26, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Performance Stock Units (PSUs)derivative | +43,750 | $0.00 | $0 | 43,750 | Sep 30, 2025 |
| Sep 26, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Performance Stock Units (PSUs)derivative | +39,150 | $0.00 | $0 | 39,150 | Sep 30, 2025 |
| Sep 26, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Performance Stock Units (PSUs)derivative | +18,150 | $0.00 | $0 | 18,150 | Sep 30, 2025 |
| Sep 26, 2025 | Sean A. McCarthy CEO | AGrant or award Performance Stock Units (PSUs)derivative | +285,000 | $0.00 | $0 | 285,000 | Sep 30, 2025 |
| Jun 13, 2025 | Christopher Ogden Chief Financial Officer | SOpen-market sale Common Stock | -1,641 | $2.95 | $4,841 | 199,385 | Jun 17, 2025 |
| Jun 13, 2025 | Marcia Belvin SVP, Chief Scientific Officer | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 286,136 | Jun 17, 2025 |
| Jun 13, 2025 | Sean A. McCarthy CEO | MOption exercise Common Stock | +150,000 | $0.00 | $0 | 1,145,195 | Jun 17, 2025 |
| Jun 16, 2025 | Marcia Belvin SVP, Chief Scientific Officer | SOpen-market sale Common Stock | -13,884 | $2.69 | $37k | 272,252 | Jun 17, 2025 |
| Jun 13, 2025 | Christopher Ogden Chief Financial Officer | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 236,885 | Jun 17, 2025 |
| Jun 16, 2025 | Sean A. McCarthy CEO | SOpen-market sale Common Stock | -55,511 | $2.69 | $149k | 1,089,684 | Jun 17, 2025 |
| Jun 13, 2025 | Marcia Belvin SVP, Chief Scientific Officer | MOption exercise Performance Stock Unitsderivative | -37,500 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 16, 2025 | Christopher Ogden Chief Financial Officer | SOpen-market sale Common Stock | -10,614 | $2.69 | $29k | 226,271 | Jun 17, 2025 |
| Jun 13, 2025 | Sean A. McCarthy CEO | MOption exercise Performance Stock Unitsderivative | -150,000 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 13, 2025 | Christopher Ogden Chief Financial Officer | MOption exercise Performance Stock Unitsderivative | -37,500 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 11, 2025 | Zhen Su director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | Matthew P. Young director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | Elaine Jones V director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | Mani Mohindru director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | Halley E Gilbert director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | Alan Ashworth director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 11, 2025 | James R Meyers director | AGrant or award Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Mar 18, 2025 | Marcia Belvin SVP, Chief Scientific Officer | SOpen-market sale Common Stock | -19,512 | $0.60 | $12k | 248,636 | Mar 20, 2025 |
| Mar 18, 2025 | Yu-Waye Chu Chief Medical Officer | SOpen-market sale Common Stock | -4,025 | $0.60 | $2,411 | 135,725 | Mar 20, 2025 |
| Mar 18, 2025 | Lloyd A Rowland General Counsel | SOpen-market sale Common Stock | -10,203 | $0.60 | $6,112 | 120,594 | Mar 20, 2025 |
| Mar 18, 2025 | Christopher Ogden Chief Financial Officer | SOpen-market sale Common Stock | -8,551 | $0.60 | $5,122 | 201,026 | Mar 20, 2025 |
| Mar 18, 2025 | Sean A. McCarthy CEO | SOpen-market sale Common Stock | -37,656 | $0.60 | $23k | 995,195 | Mar 20, 2025 |
| Feb 4, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Common Stock | +56,000 | $0.00 | $0 | 82,250 | Feb 6, 2025 |
| Feb 4, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 152,077 | Feb 6, 2025 |
| Feb 4, 2025 | Sean A. McCarthy CEO | AGrant or award Common Stock | +180,000 | $0.00 | $0 | 837,851 | Feb 6, 2025 |
| Feb 4, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 205,648 | Feb 6, 2025 |
| Feb 4, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 139,750 | Feb 6, 2025 |
| Feb 4, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 263,148 | Feb 6, 2025 |
| Feb 4, 2025 | Sean A. McCarthy CEO | AGrant or award Common Stock | +195,000 | $0.00 | $0 | 1,032,851 | Feb 6, 2025 |
| Feb 4, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 209,577 | Feb 6, 2025 |
| Feb 4, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 6, 2025 |
| Feb 4, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +238,000 | $0.00 | $0 | 238,000 | Feb 6, 2025 |
| Feb 4, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Feb 6, 2025 |
| Feb 4, 2025 | Marcia Belvin SVP, Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 6, 2025 |
| Feb 4, 2025 | Yu-Waye Chu Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 6, 2025 |
| Feb 4, 2025 | Sean A. McCarthy CEO | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Feb 6, 2025 |
| Feb 4, 2025 | Christopher Ogden Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 6, 2025 |
| Feb 4, 2025 | Sean A. McCarthy CEO | AGrant or award Stock Option (Right to Buy)derivative | +390,000 | $0.00 | $0 | 390,000 | Feb 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Alan Ashworthdirector
- Marcia BelvinSVP, Chief Scientific Officer
- Yu-Waye ChuChief Medical Officer
- Halley E Gilbertdirector
- Elaine Jones Vdirector
- Rachael LesterChief Business Officer
- Sean A. McCarthyCEO
- James R Meyersdirector
- Mani Mohindrudirector
- Christopher OgdenChief Financial Officer
- Lloyd A RowlandGeneral Counsel
- Zhen Sudirector
- Matthew P. Youngdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.